Key result
Preoperative aspirin therapy significantly reduced the risk of 30-day mortality (OR 0.611) compared to no aspirin in patients undergoing cardiac surgery.
Why the study?
Does preoperative aspirin use reduce major cardiocerebral complications and 30-day mortality in patients undergoing cardiac surgery?
Population
2,868 patients undergoing cardiac surgery
Comparison
Aspirin use within 5 days preceding surgery vs No aspirin use within 5 days preceding surgery
Design
Cohort
Follow-up
30-day
Authors
Loading...
Does not support changing preoperative aspirin protocols; leaves open confirmation of mortality benefit in randomized trials.
Cohort (n=2,868)
Yes
Does preoperative aspirin use reduce major cardiocerebral complications and 30-day mortality in patients undergoing cardiac surgery?
Effect estimate: OR 0.611 (95% CI 0.391-0.956)
Absolute Event Rate: 3.5% vs 6.5%
p-value: p=0.031
Preoperative aspirin use within 5 days of cardiac surgery is associated with reduced 30-day mortality, renal failure, and major adverse cardiocerebral events.
Cao et al. (2011) conducted a cohort in Cardiac surgery (n=2,868). Preoperative aspirin vs. No preoperative aspirin was evaluated on 30-day all-cause mortality (OR 0.611, 95% CI 0.391-0.956, p=0.031). Preoperative aspirin therapy significantly reduced the risk of 30-day mortality (OR 0.611) compared to no aspirin in patients undergoing cardiac surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: